<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43450">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01791725</url>
  </required_header>
  <id_info>
    <org_study_id>ELND005-DS201</org_study_id>
    <nct_id>NCT01791725</nct_id>
  </id_info>
  <brief_title>A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia</brief_title>
  <acronym>DS201</acronym>
  <official_title>A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elan Pharma International Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Elan Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind, placebo-controlled, parallel-group,
      three-arm, multicenter study of the safety and PK of ELND005 administered orally for 4
      weeks.  This study will enroll Down Syndrome patients 18 to 45 years of age (inclusive)
      without dementia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of adverse events (TEAE, SAE)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline in physical and neurological examinations</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma ELND005 concentrations</measure>
    <time_frame>4 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>ELND005 PK profile to optimize PK model including patient population</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cognitive Outcome</measure>
    <time_frame>4 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rapid Assessment for Development Disabilities (RADD)</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional Outcomes</measure>
    <time_frame>4 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vineland Adaptive Behavior Scale, Second Edition (VABS-II)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Down Syndrome</condition>
  <arm_group>
    <arm_group_label>ELND005 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ELND005 250 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ELND005 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ELND005 250 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELND005</intervention_name>
    <arm_group_label>ELND005 BID</arm_group_label>
    <arm_group_label>ELND005 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 - 45 years of age

          -  Has an IQ of &gt; 40 (K-BIT)

          -  Able and willing to have a brain MRI

        Exclusion Criteria:

          -  Symptoms of dementia or worsening cognition over the past year.

          -  Has a history of hepatitis B, hepatitis C, or HIV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick Kesslak, Ph D</last_name>
    <phone>415-590-0078</phone>
    <email>patrick.kesslak@elan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0949</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>February 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Down Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
